on NEOVACS (EPA:ALNEV)
Neovacs seeks investors for Arnity Therapeutics
On July 1, 2025, Neovacs announced the intensification of its development program to encourage investment in Arnity Therapeutics. This company, specializing in the development of treatments for asthma and allergies, aims to attract unlisted funds. Neovacs intends to attract approximately €20 million to advance a Phase I/IIa clinical trial in asthma. Vincent Serra, Chief Scientific Officer of Neovacs, is actively pursuing this goal, having participated in the BIO 2025 trade show in Boston.
Expressions of interest have already been received from various investors, and Neovacs is working on the legal creation of Arnity. If successful, Neovacs will refocus on its investment role.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NEOVACS news